Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Hyqvia Market Revenue Outlook: What CAGR Is Expected Through 2030?
The expansion observed during the historical period was driven by several factors, including the constraints associated with intravenous immunoglobulin therapy, the elevated infection risk faced by patients with primary immunodeficiency (PI), the early uptake of subcutaneous immunoglobulins, the demand for enhanced quality of life, and the development of specialized immunology care.
The expansion observed during the forecast period is driven by a higher number of diagnosed primary immunodeficiency cases, the broadening of home healthcare services, a greater focus on managing pediatric primary immunodeficiency, a growing preference for extended dosing intervals, and the rise of specialty pharmacy distribution. Key developments shaping this period include a transition to less frequent immunoglobulin administration, increased utilization of infusion therapies provided at home, a surge in demand for products combining immunotherapies, enhanced ease for patients undergoing primary immunodeficiency treatment, and a wider uptake of subcutaneous immunoglobulin options.
Download A Free Sample Report For Comprehensive Market Insights:
Hyqvia Market Growth Drivers And Industry Catalysts
The anticipated expansion of the hyqvia market is being fueled by the rising incidence of autoimmune diseases. These disorders occur when the immune system erroneously attacks the body’s own healthy cells, tissues, or organs, resulting in inflammation and impaired function. The increase in autoimmune conditions is linked to several contributing factors, such as genetic susceptibility, environmental triggers, shifts in dietary habits, heightened exposure to pollutants, and enhanced diagnostic methods. Hyqvia is utilized in treating autoimmune diseases because it provides immunoglobulin therapy that helps regulate the immune system and curtail aberrant immune responses directed against the body’s own tissues. As an example, in May 2023, a study published by the NIHR Imperial Biomedical Research Centre, a UK-based government research institute and agency, examined anonymized electronic health records from 22 million individuals across the UK to analyze 19 common autoimmune diseases, which affect roughly 10% of the population—13% of women and 7% of men. Consequently, the growing prevalence of autoimmune diseases is propelling the hyqvia market forward.
The hyqvia market is expected to be driven forward by an upsurge in healthcare investment. Healthcare investment involves the commitment of financial resources to businesses, technologies, research, and infrastructure within the healthcare sector, all aimed at enhancing patient outcomes, fostering innovation, and stimulating industry expansion. The increase in healthcare investment is attributable to a growing demand for advanced medical therapies, technological breakthroughs, an aging demographic, and efforts to broaden global healthcare access and improve outcomes. This investment positively influences HYQVIA by facilitating its ongoing development, securing regulatory approvals, and expanding its availability, thereby promoting its use in treating immunodeficiency and chronic inflammatory demyelinating polyneuropathy (CIDP). By way of illustration, in April 2025, the American Medical Association, a non-profit organization based in the US, reported that U.S. health spending surged by 7.5% in 2023, totaling $4.9 trillion—or $14,570 per individual—which represents a significant acceleration compared to the 4.6% increase observed in 2022. Thus, the rising healthcare investment is advancing the hyqvia market.
Hyqvia Market Segment Outlook: Which Categories Are Expanding The Fastest?
The hyqvia market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Distribution Channel: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Retail Pharmacies
3) By Application: Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Other Applications
Hyqvia Market Trends Influencing Long-Term Demand
Key developments in the Hyqvia space are centered on creating advanced therapies like immune globulin infusion to address chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI). This treatment works by delivering antibody-rich plasma proteins to manage immune deficiencies and autoimmune conditions. For example, Takeda Pharmaceutical Company Ltd., headquartered in Japan, revealed in January 2024 that the U.S. Food and Drug Administration (FDA) had granted approval for its product, HYQVIA® (immune globulin infusion 10% [human] with recombinant human hyaluronidase), as a maintenance therapy for adults suffering from CIDP. This FDA authorization allows HYQVIA to be employed in preventing relapses of neuromuscular disability and impairment stemming from CIDP, a rare neuromuscular disorder impacting roughly five to seven people per 100,000 in the United States.
Hyqvia Market Key Companies And Competitive Benchmarking
Major companies operating in the hyqvia market are Takeda Pharmaceutical Company Limited
Access The Complete Hyqvia Market Report:
Hyqvia Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the hyqvia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the hyqvia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model